vs

Side-by-side financial comparison of International Money Express, Inc. (IMXI) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

International Money Express, Inc. is the larger business by last-quarter revenue ($147.4M vs $83.1M, roughly 1.8× PROCEPT BioRobotics Corp). International Money Express, Inc. runs the higher net margin — 6.1% vs -38.1%, a 44.1% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -10.5%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs -1.0%).

American Express Company or Amex is an American bank holding company and multinational financial services corporation that specializes in payment cards. It is headquartered at 200 Vesey Street, also known as American Express Tower, in the Battery Park City neighborhood of Lower Manhattan.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

IMXI vs PRCT — Head-to-Head

Bigger by revenue
IMXI
IMXI
1.8× larger
IMXI
$147.4M
$83.1M
PRCT
Growing faster (revenue YoY)
PRCT
PRCT
+30.7% gap
PRCT
20.2%
-10.5%
IMXI
Higher net margin
IMXI
IMXI
44.1% more per $
IMXI
6.1%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
-1.0%
IMXI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IMXI
IMXI
PRCT
PRCT
Revenue
$147.4M
$83.1M
Net Profit
$8.9M
$-31.6M
Gross Margin
64.9%
Operating Margin
7.9%
-4.1%
Net Margin
6.1%
-38.1%
Revenue YoY
-10.5%
20.2%
Net Profit YoY
-41.9%
-27.9%
EPS (diluted)
$0.29
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMXI
IMXI
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$147.4M
$76.4M
Q3 25
$154.9M
$83.3M
Q2 25
$161.1M
$79.2M
Q1 25
$144.3M
$69.2M
Q4 24
$164.8M
$68.2M
Q3 24
$171.9M
$58.4M
Q2 24
$171.5M
$53.4M
Net Profit
IMXI
IMXI
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$8.9M
$-29.8M
Q3 25
$5.0M
$-21.4M
Q2 25
$11.0M
$-19.6M
Q1 25
$7.8M
$-24.7M
Q4 24
$15.4M
$-18.9M
Q3 24
$17.3M
$-21.0M
Q2 24
$14.0M
$-25.6M
Gross Margin
IMXI
IMXI
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
IMXI
IMXI
PRCT
PRCT
Q1 26
-4.1%
Q4 25
7.9%
-40.6%
Q3 25
6.8%
-27.8%
Q2 25
12.1%
-28.0%
Q1 25
9.8%
-39.7%
Q4 24
15.0%
-28.9%
Q3 24
16.2%
-38.4%
Q2 24
13.4%
-50.3%
Net Margin
IMXI
IMXI
PRCT
PRCT
Q1 26
-38.1%
Q4 25
6.1%
-39.1%
Q3 25
3.2%
-25.7%
Q2 25
6.8%
-24.7%
Q1 25
5.4%
-35.8%
Q4 24
9.3%
-27.6%
Q3 24
10.1%
-35.9%
Q2 24
8.2%
-48.0%
EPS (diluted)
IMXI
IMXI
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.29
$-0.54
Q3 25
$0.17
$-0.38
Q2 25
$0.37
$-0.35
Q1 25
$0.25
$-0.45
Q4 24
$0.49
$-0.34
Q3 24
$0.53
$-0.40
Q2 24
$0.42
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMXI
IMXI
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$168.7M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$161.1M
$347.7M
Total Assets
$517.7M
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMXI
IMXI
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$168.7M
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$130.5M
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
IMXI
IMXI
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
IMXI
IMXI
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$161.1M
$365.9M
Q3 25
$149.7M
$380.3M
Q2 25
$142.3M
$385.8M
Q1 25
$139.2M
$389.2M
Q4 24
$134.9M
$402.2M
Q3 24
$141.8M
$241.2M
Q2 24
$142.4M
$251.8M
Total Assets
IMXI
IMXI
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$517.7M
$508.1M
Q3 25
$478.7M
$511.5M
Q2 25
$518.0M
$513.1M
Q1 25
$490.6M
$519.4M
Q4 24
$462.4M
$534.0M
Q3 24
$480.9M
$374.1M
Q2 24
$612.4M
$374.4M
Debt / Equity
IMXI
IMXI
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMXI
IMXI
PRCT
PRCT
Operating Cash FlowLast quarter
$-15.6M
Free Cash FlowOCF − Capex
$-20.0M
FCF MarginFCF / Revenue
-13.6%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
-1.75×
TTM Free Cash FlowTrailing 4 quarters
$15.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMXI
IMXI
PRCT
PRCT
Q1 26
Q4 25
$-15.6M
$-10.3M
Q3 25
$-28.7M
$-6.6M
Q2 25
$39.9M
$-15.0M
Q1 25
$41.3M
$-17.0M
Q4 24
$-4.9M
$-32.4M
Q3 24
$29.3M
$-18.8M
Q2 24
$-19.6M
$-15.7M
Free Cash Flow
IMXI
IMXI
PRCT
PRCT
Q1 26
Q4 25
$-20.0M
$-12.2M
Q3 25
$-35.5M
$-9.5M
Q2 25
$35.3M
$-17.8M
Q1 25
$36.0M
$-18.8M
Q4 24
$-8.8M
$-33.6M
Q3 24
$23.4M
$-19.0M
Q2 24
$-26.2M
$-16.8M
FCF Margin
IMXI
IMXI
PRCT
PRCT
Q1 26
Q4 25
-13.6%
-15.9%
Q3 25
-22.9%
-11.4%
Q2 25
21.9%
-22.5%
Q1 25
25.0%
-27.2%
Q4 24
-5.4%
-49.2%
Q3 24
13.6%
-32.6%
Q2 24
-15.3%
-31.4%
Capex Intensity
IMXI
IMXI
PRCT
PRCT
Q1 26
Q4 25
3.0%
2.4%
Q3 25
4.4%
3.4%
Q2 25
2.8%
3.5%
Q1 25
3.7%
2.7%
Q4 24
2.4%
1.7%
Q3 24
3.4%
0.4%
Q2 24
3.9%
2.0%
Cash Conversion
IMXI
IMXI
PRCT
PRCT
Q1 26
Q4 25
-1.75×
Q3 25
-5.78×
Q2 25
3.63×
Q1 25
5.31×
Q4 24
-0.32×
Q3 24
1.69×
Q2 24
-1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IMXI
IMXI

Wire Transfer And Money Order$121.2M82%
Other$21.0M14%
Financial Service Other$5.2M4%

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons